Evidence map›Paper›PMID 28531130›Full record

ArticleNutrients2017

Comparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity.

Sapna Patel, Yasser Faraj, Debra K Duso, William W Reiley, Erik A Karlsson, Stacey Schultz-Cherry, Michael Vajdy

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Safety and Efficacy of thePharmaceutics · 2022
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sapna PatelEpitoGenesis, Inc., 933 Hartford Turnpike Vernon, Hartford, CT 06066, USA. spatel1486@gmail.com.
Yasser FarajEpitoGenesis, Inc., 933 Hartford Turnpike Vernon, Hartford, CT 06066, USA. yasserfaraj92@gmail.com.
Debra K DusoTICRO at Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA. dduso@trudeauinstitute.org.
William W ReileyTICRO at Trudeau Institute, 154 Algonquin Ave, Saranac Lake, NY 12983, USA. wreiley@trudeauinstitute.org.
Erik A KarlssonDepartment of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. erik.karlsson@stjude.org.
Stacey Schultz-CherryDepartment of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA. Stacey.Schultz-Cherry@STJUDE.ORG.
Michael VajdyEpitoGenesis, Inc., 933 Hartford Turnpike Vernon, Hartford, CT 06066, USA. vajdy@epitogenesis.com.
EpitoGenesis (United States) · USSt. Jude Children's Research Hospital · USTrudeau Institute · US

Funding

NIAID NIH HHS HHSN272201400031C
6 · The paper itself

Abstract

Non-replicating vaccines, such as those based on recombinant proteins, require adjuvants and delivery systems, which have thus far depended on mimicking pathogen danger signals and strong pro-inflammatory responses. In search of a safer and more efficacious alternative, we tested whether vaccinations with influenza recombinant hemagglutinin (HA) mixed with a novel vegetable oil in water emulsion adjuvant (Natural Immune-enhancing Delivery System, NIDS), based on the immune-enhancing synergy of vitamins A and E and a catechin, could protect against intra-nasal challenge with live influenza virus. Vaccinations of inbred Brag Albino strain c (BALB/c) mice, with HA mixed with NIDS compared to other adjuvants, i.e., a squalene oil in water emulsion (Sq. oil), and the Toll Like Receptor 3 (TLR3) agonist Poly (I:C), induced significantly lower select innate pro-inflammatory responses in serum, but induced significantly higher adaptive antibody and splenic T Helper 1 (TH1) or TH2, but not TH17, responses. Vaccinations with NIDS protected against infection, as measured by clinical scores, lung viral loads, and serum hemagglutination inhibition titers. The NIDS exhibited a strong dose sparing effect and the adjuvant action of NIDS was intact in the outbred CD1 mice. Importantly, vaccinations with the Sq. oil, but not NIDS, induced a significantly higher Serum Amyloid P component, an acute phase reactant secreted by hepatocytes, and total serum IgE. Thus, the NIDS may be used as a clinically safer and more efficacious vaccine adjuvant against influenza, and potentially other infectious diseases.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralCatechinImmunization ScheduleInfluenza VaccinesMiceOrthomyxoviridae InfectionsVaccinesViral LoadVitamin AVitamin EAdjuvants, ImmunologicAntibodies, ViralCatechinInfluenza VaccinesVaccinesVitamin AVitamin Eadjuvantcatechinflavonoidimmunityinfluenzanaturalvaccinevitamin Avitamin E

Identifiers

PMID28531130
PMCPMC5452246
OpenAlexW2615985838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.